Xtant Medical (XTNT) news

Recent news

Xtant Medical announces exclusive partnership with BioHorizons to expand access to Xtant's allogeneic growth factor into the dental market

Xtant Medical raises FY 2026 revenue guidance to a range of $101-$105M

Xtant Medical (NASDAQ: XTMD) has raised its full-year 2026 revenue guidance to a range of $101 million to $105 million, reflecting strong performance across its product lines and continued demand in the medical device sector. The updated forecast, announced on May 13, 2026, indicates confidence in…

AInvest Wire · May 13, 2026

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by